Clinical Trial Update: Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated imatinib (Gleevec) for chronic myelomonocytic leukemia, chronic myeloid leukemia, and atypical chronic myeloid leukemia; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED